학술논문
RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA
Document Type
article
Author
Mellinghoff, Ingo; Maher, Elizabeth; Wen, Patrick; Cloughesy, Timothy; Peters, Katherine; Choi, Changho; Ellingson, Benjamin; Lin, Alexander; Li, Yan; Soher, Brian; Young, Robert; Steelman, Lori; Le, Kha; Yin, Feng; Wu, Bin; Lu, Min; Zhang, Yanwei; Nicolay, Brandon; Schoenfeld, Steven; Yen, Katharine; Pandya, Shuchi; Clarke, Jennifer
Source
Neuro-oncology. 20(Suppl 6)
Subject
Language
Abstract
Abstract Mutations in isocitrate dehydrogenase (mIDH) are common in lower-grade glioma (LGG; mIDH1, 80%; mIDH2, 4%) and lead to epigenetic and genetic changes that promote oncogenesis via production of the oncometabolite 2-hydroxyglutarate (2-HG). AG-120 (ivosidenib) is a first-in-class oral mIDH1 inhibitor associated with a favorable safety profile in an ongoing phase 1 study in 66 glioma patients. AG-881 is a brain-penetrant oral mIDH1/2 inhibitor with an acceptable safety profile at dose levels